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ABSTRACT
Objectives To compare standard high flow oxygen
treatment with titrated oxygen treatment for patients with
an acute exacerbation of chronic obstructive pulmonary
disease in the prehospital setting.
DesignClusterrandomisedcontrolledparallelgrouptrial.
Setting Ambulance service in Hobart, Tasmania,
Australia.
Participants 405 patients with a presumed acute
exacerbation of chronic obstructive pulmonary disease
who were treated by paramedics, transported, and
admitted to the Royal Hobart Hospital during the trial
period; 214 had a diagnosis of chronic obstructive
pulmonarydiseaseconfirmedbylungfunctiontestsinthe
previous five years.
Interventions High flow oxygen treatment compared with
titrated oxygen treatment in the prehospital (ambulance/
paramedic) setting.
Main outcome measure Prehospital or in-hospital
mortality.
Results In an intention to treat analysis, the risk of death
was significantly lower in the titrated oxygen arm
compared with the high flow oxygen arm for all patients
(high flow oxygen n=226; titrated oxygen n=179) and for
the subgroup of patients with confirmed chronic
obstructive pulmonary disease (high flow n=117; titrated
n=97). Overall mortality was 9% (21 deaths) in the high
flow oxygen arm compared with 4% (7 deaths) in the
titrated oxygen arm; mortality in the subgroup with
confirmedchronicobstructivepulmonarydiseasewas9%
(11 deaths) in the high flow arm compared with 2% (2
deaths) in the titrated oxygen arm. Titrated oxygen
treatment reduced mortality compared with high flow
oxygen by 58% for all patients (relative risk 0.42, 95%
confidence interval 0.20 to 0.89; P=0.02) and by 78% for
the patients with confirmed chronic obstructive
pulmonary disease (0.22, 0.05 to 0.91; P=0.04). Patients
withchronicobstructivepulmonarydiseasewhoreceived
titrated oxygen according to the protocol were
significantlylesslikelytohaverespiratoryacidosis(mean
difference in pH 0.12 (SE 0.05); P=0.01; n=28) or
hypercapnia (mean difference in arterial carbon dioxide
pressure −33.6 (16.3) mm Hg; P=0.02; n=29) than were
patients who received high flow oxygen.
Conclusions Titrated oxygen treatment significantly
reduced mortality, hypercapnia, and respiratory acidosis
comparedwithhighflowoxygeninacuteexacerbationsof
chronic obstructive pulmonary disease. These results
provide strong evidence to recommend the routine use of
titrated oxygen treatment in patients with breathlessness
and a history or clinical likelihood of chronic obstructive
pulmonary disease in the prehospital setting.
Trial registration Australian New Zealand Clinical Trials
Register ACTRN12609000236291.
INTRODUCTION
Chronicobstructivepulmonarydiseaseisamajorpub-
lic health problem in many countries. The World
HealthOrganizationestimatesthat210millionpeople
have moderate to severe chronic obstructive pulmon-
ary disease and that three million people died of the
condition in 2005.
1 Chronic obstructive pulmonary
disease is associated with a substantial economic bur-
den; estimates of cost include $49.9 (£31.5; €36.3) bil-
lionin the UnitedStates in2010 and$1.5billionin the
UnitedKingdomin2004.
23Thecourseofthediseaseis
characterised by episodes, known as acute exacerba-
tions, when symptoms of cough, sputum production,
and breathlessness become much worse. These are a
frequent cause of admission to hospital, estimated to
cost approximately $73 billion a year in the United
States and $700 million a year in Australia and
Canada.
4-6 Standard prehospital management of an
acute exacerbation of chronic obstructive pulmonary
disease includes nebulised bronchodilators (usually
driven by 6-8 l/min of oxygen), corticosteroids, and
oxygen.
Oxygen is commonly administered to patients with
an acute exacerbation of chronic obstructive pulmon-
ary disease, as well as for a range of other medical
emergencies,
78andcansavelivesbypreventingsevere
hypoxaemia. Administration of high flow oxygen to
normal people leads to an increase in the minute ven-
tilation (the volume of air inspired into or expired out
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BMJ | ONLINE FIRST | bmj.com page 1 of 8of the lungs in one minute) and a decrease in end tidal
carbon dioxide concentration.
910 However, even in
patientswithstablechronicobstructivepulmonarydis-
ease, hyperoxia leads to a decrease in minute ventila-
tion and an increase in transcutaneous carbon
dioxide.
11 These changes are postulated to occur as a
result of either depression of ventilation or worsening
inequality in ventilation-perfusion due to recruitment
ofpoorlyventilatedlungunits(alveolusandassociated
pulmonarycapillarieswheregasexchangetakesplace)
by reversal of local hypoxic pulmonary vasoconstric-
tion subsequently releasing sequestered carbon
dioxide.
8 Oxygen induced changes in carbon dioxide
concentrations in chronic obstructive pulmonary dis-
ease were first shown in 1955,
12 several years after a
report on the deleterious effects of oxygen in this
condition.
13 Campbell was then fundamental in estab-
lishingthein-hospitalpracticeoftitratingoxygentreat-
ment by using venturi masks.
14 Subsequently,
mortalityinacuteexacerbationsofchronicobstructive
pulmonary disease was reported to be associated with
an increase in chronic stable levels of arterial carbon
dioxide pressure, rather than the absolute level of
hypercapnia.
15
More recently, audits of hospital management have
shownthattheadministrationofhighflowoxygendur-
ing acute exacerbations of chronic obstructive pul-
monary disease has been associated with increases in
mortality, length of hospital stay, requirement for ven-
tilation, and admission to high dependency units.
16-20
Furthermore, the use of titrated oxygen treatment has
beenassociatedwithlessacidosis,alowerrequirement
for assisted ventilation, and reduced mortality.
1520 A
one year prevalence study showed that the injudicious
use of oxygen treatment caused acidosis in patients
with acute exacerbations of chronic obstructive pul-
monary disease, but a proportion of these patients
were rapidly able to correct their pH once the fraction
ofinspiredoxygenwasreduced.
19Despitetheaccumu-
latingevidence,highflowoxygentreatmentcontinued
to be the standard of care in Australia and other coun-
tries up to the time this trial started.
7172120 In recent
years, awareness of the potential harm of routine use
of high flow oxygen has increased, and attempts have
beenmadetomodifypractice.Concernabouttherou-
tineuseofhighflowoxygentorelievebreathlessnessin
emergencysettingshaspromptedthereleaseofthefirst
international guidelines for the emergency use of
oxygen,
8 but the need for randomised controlled trials
is widely acknowledged.
816192223 A recent Cochrane
review on oxygen treatment and acute exacerbations
of chronic obstructive pulmonary disease in the pre-
hospital setting identified two ongoing trials, reinfor-
cing the medical community’s recognition of the
need for evidence in this area.
222425
Despite published guidelines, the lack of clear evi-
denceshowingthebenefitoftitratedoxygentreatment
may be responsible for the lack of widespread cultural
change among practitioners, authorities, and opinion
leaders. The difficulty in modifying practice in the
prehospital setting is compounded by the lack of
equipment capable of delivering controlled oxygen
treatment while administering nebulised drugs in
ambulances. This study was motivated by the need
for quantitative evidence on the dangers of high flow
oxygen, to support recommendations for the use of
titrated oxygen treatment for patients with an acute
exacerbation of chronic obstructive pulmonary dis-
ease. Our ultimate objective is to improve the quality
of care for patients. The aim of this study was to com-
parestandardhighflowoxygentreatmentwithtitrated
oxygen treatment for patients with an acute exacerba-
tion of chronic obstructive pulmonary disease in the
prehospital setting.
METHODS
Participants
The study populationcomprised people aged 35 years
or older with breathlessness and a history or risk of
chronic obstructive pulmonary disease. Paramedics
at the site of the emergency determined the diagnosis
on the basis of appropriate acute symptoms, a history
of chronic obstructive pulmonary disease (or emphy-
sema) from the patient, or a greater than 10 pack year
historyofsmoking.ThestudyperiodwasJune 2006to
July 2007, and all participants were transported by
ambulance and admitted to the Royal Hobart Hospi-
tal. This is located in the Tasmanian state capital of
Hobartandisthemajorgeneralhospitalservingsouth-
ern Tasmania (population approximately 250000).
Randomisation
The study was a randomised, controlled, parallel
group trial with two arms: paramedics in the active
arm administered titrated oxygen treatment and
those in the control arm administered conventional
high flow oxygen treatment. We invited paramedics
fromthe Tasmanian Ambulance Serviceto participate
in the study and used cluster randomisation to assign
them to one of the treatment groups. We used compu-
terised random number generation after stratification
byrurality,toreducedifferencesassociatedwithtrans-
portation time between urban and rural areas. This
procedure ensured that treatment allocation was con-
cealed before randomisation. Neither paramedics nor
the research team were blinded to treatment after ran-
domisation.Insituationsinwhichmultipleparamedics
attended a patient and had been allocated to different
study arms, the paramedic responsible for treatment
wastodeliveroxygenaccordingtohisorhertreatment
allocation. We informed nursing and medical staff at
the emergency department of Royal Hobart Hospital
aboutthe trialandaskedthemtotakeanarterialblood
gas sample from each patient immediately on arrival.
Weaskedparamedicstoinformhospitalstaffonarrival
that a patient was enrolled in the study and to request
the same ongoing oxygen treatment until an arterial
blood gas sample had been taken. Hospital staff were
thusnotblindedtothetreatmentallocation.Theethics
committeewaivedpatients’consent,forpragmaticrea-
sonsinanacute emergencysituationandbecausehigh
flow oxygen treatment was the default standard
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the study started.To avoid contamination acrosstreat-
mentgroups,wechoseparamedicsratherthanpatients
as the unit of randomisation.
Interventions
Patients in the active arm received titrated oxygen
treatmentdeliveredby nasalprongstoachievearterial
oxygen saturations between 88% and 92%, with con-
current bronchodilator treatment administered by a
nebuliser driven by compressed air (Walkie nebulisa-
tion air compressors, FlaemNova, Milan, Italy) and
delivered via a facemask over the nasal prongs. The
control arm received high flow oxygen treatment
(8-10 l/min) administered by a non-rebreather face
mask and bronchodilators delivered by nebulisation
with oxygen at flows of 6-8 l/min. Pulse oximeters
were used to measure oxygen saturations and titrate
oxygen to target saturations in the active arm. Oxi-
meters were also used to measure oxygen saturation
in the high flow oxygen arm. The oximeters were
built into the MRL (Welch Allyn, New York, USA)
and MRX (Phillips Medical Systems, Andover,
USA), had no alarm boundaries programmed, and
had a visual readout only. Oxygen saturations were
recorded on the ambulance report form.
All patients received other standard treatment
according to Tasmanian Ambulance Service guide-
lines, including basic support, nebulised bronchodila-
tors(salbutamol5mgmadeupin2.5mlnormalsaline,
ipratropium bromide500 μgmadeupwith 2.5ml nor-
mal saline), dexamethasone 8 mg intravenously, and,
where necessary, salbutamol 200-300 mg intra-
venously or 500 mg intramuscularly.
Data collection
Patients entered into the study were identified by two
means.Paramedicsannotatedambulancereportforms
to indicate patients who were entered into the trial to
facilitate subsequent identification of these patients by
the research team. The emergency department at
Royal Hobart Hospital also supplied a list of all
patients transported by ambulance with a respiratory
diagnosis, which the research team cross checked
against ambulance records to compile a complete list
of patients included in the study. We retrospectively
defined a subgroup with chronic obstructive pulmon-
arydiseaseasthosepatientswithadefinitediagnosisof
chronic obstructive pulmonary disease, as defined by
national guidelines.
5 A respiratory physician blind to
treatment allocation reviewed lung function data and
smoking history, from private and public medical
records. Only lung function data recorded in the five
yearsbeforestudyentrywereconsidered.Patientswith
no lung function data or who did not fulfil spirometric
criteria for chronic obstructive pulmonary disease
were excluded from the subgroup analyses. Royal
Hobart Hospital provided data on arterial blood gas
results taken within 30 minutes of arrival at the emer-
gency department, requirement for invasive (endo-
tracheal intubation) or non-invasive ventilation, the
length of stay in hospital, and mortality. Length of
treatmentintheambulanceandoxygensaturationdur-
ing prehospital management came from the Tasma-
nian Ambulance Service’s records. Data were
missing from both the ambulance and hospital patient
records, so the denominators vary among analyses.
Statistical analysis
We used the oxygen dissociation curve and Kelman’s
equationtodeterminewhetherbloodgassampleswere
arterial or venous if this had not been recorded.
26 We
comparedthemeasuredarterialoxygenconcentrations
withtheconcentrationscalculatedfrompulseoximetry
at the time of the blood gas sample. We took a differ-
ence greater than 5% between the calculated and mea-
sured oxygen concentrations to indicate that the blood
gaswasa venoussample. Forvenous samples,we used
the formulations described by Ak to estimate arterial
values for pH, carbon dioxide, and bicarbonate.
27 We
used non-paired Student’s t tests to compare arterial
and converted venous blood gases. As no significant
differences existed between arterial or converted
venous samples for pH, carbon dioxide, or bicarbo-
nate, we combined them for subsequent analyses. We
could not convert venous oxygen concentrations, as
comparative arterial oxygen concentrations are not
provided in the conversion equations, and we thus
report only measured arterial oxygen concentrations.
Theprimaryoutcomewasprehospitalandin-hospital
mortality.Weusedlogbinomialregressiontocompare
the risk of death for patients in the two treatment arms.
Wecomparedsecondaryoutcomes—namely, length of
hospital stay and blood gas measurements (pH, arterial
carbon dioxide, bicarbonate, and arterial oxygen)—by
using Student’s t tests after transformation to remove
skewness. We combined ventilation categories (inva-
sive and non-invasive), as the number of observations
wassmall,andusedlogbinomialregressiontocompare
them.Webasedinitialanalysesontheintentiontotreat
principleandrestrictedafurthersetofperprotocolana-
lyses to patients who received treatment that complied
withthestudyprotocol.Wedidallanalysesforallstudy
patients and for the subgroup of patients with chronic
obstructivepulmonarydiseaseconfirmedbylungfunc-
tion tests. We adjusted standard errors to account for
any correlation between observations for the same
Table 1 |Baseline characteristics of treating paramedics. Values are numbers (percentages)
unless stated otherwise
Characteristic
Control (high flow oxygen)
(n=30)
Active (titrated oxygen)
(n=32)
Location:
Urban 23 (77) 23 (72)
Rural 7 (23) 9 (28)
Qualification:
Paramedic 10 (33) 8 (25)
Intensive care paramedic 20 (67) 24 (75)
Mean (SD) years of experience 15.5 (8.3) 16.7 (12.1)
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for Windows for all analyses and considered a P value
of 0.05 to be statistically significant.
Fortheprimaryoutcomemeasure,mortality,wedid
powercalculationsassuminga12%absolutedifference
in mortality between treatment arms, based on the
study by Denniston et al.
16 We calculated that a total
of 200 participants (100 in each of two equal sized
groups) would provide 83% power to detect a 70%
reduction in mortality, from 14% in the high flow oxy-
gen treatment arm to 2% in the titrated oxygen treat-
ment arm. This sample size would also provide 94%
power to detect a difference in arterial carbon dioxide
pressure of 10 mm Hg (common SD 20 mm Hg)
between the two groups. We allowed for a 25% drop-
out rate and thus needed a minimum of 135 partici-
pants in each arm.
RESULTS
We received consent to participate from 62 (98%) of
the 63 full time paramedic staff, who had a one
month familiarisation and training period before data
collectionstarted.Paramedicswereequallydistributed
betweenthetwotreatmentarmswithregardtorurality,
training, and experience (table 1). The paramedics
transported 405 eligible patients to the Royal Hobart
Hospital during the 13 month study period: 226 were
treated by paramedics assigned to the high flow oxy-
gen arm and 179 by those in the titrated oxygen arm.
Thesubgroupofpatientswithchronicobstructive pul-
monary disease confirmed by lung function tests con-
tained 214 of the study patients: 117 were treated by
paramedics assigned to the high flow oxygen arm and
97 by those in the titrated oxygen arm (figure).
Seventy-nine (37%) randomised patients, 25 in the
high flow arm and 54 in the titrated arm, did not
receive treatment according to protocol, leaving 43
patients in the titrated oxygen arm and 92 patients in
thehighflowoxygenarmfortheperprotocolanalyses.
Baseline characteristics for all patients and for the
subgroup of patients with confirmed chronic obstruc-
tive pulmonary disease did not differ significantly
between the treatment arms in terms of age, sex, initial
oxygen saturation, or prehospital treatment time
(table 2).Patientsinthechronicobstructivepulmonary
disease subgroup did not differ significantly between
groups in per cent predicted forced expiratory volume
in one second or smoking history (table 2). Blood gas
samples were taken after arrival at hospital in only 122
(57%)patients,andoftheseonly23(19%)werearterial
samples drawn within 30 minutes of arrival.
In the intention to treat analysis for all patients, we
found a significant difference between the two treat-
ment arms for mortality (relative risk 0.42, 95% confi-
denceinterval0.20to0.89;P=0.02)(table 3).Mortality
was 9% (21 deaths) in the high flow oxygen arm com-
pared with 4% (seven deaths) in the titrated oxygen
arm. In the intention to treat analysis for the subgroup
with confirmed chronic obstructive pulmonary dis-
ease,wealsofoundasignificantdifferenceinmortality:
9%(11deaths)inthehighflowarmcomparedwith2%
(two deaths) in the titrated oxygen arm (relative risk
0.22, 0.05 to 0.91; P=0.04) (table 3). All deaths
occurred after arrival at hospital, including two in the
emergency department and two in the intensive care
unit.Respiratoryfailurewastheprimarycauseofdeath
inallcases,andapproximately70%ofdeathsoccurred
within the first five days of admission for both treat-
ment arms.
In the intention to treat analysis for secondary out-
comes, we found no significant differences between
treatment arms for length of hospital stay or require-
ment for ventilation for all patients or the subgroup
withconfirmedchronicobstructivepulmonarydisease
(table 3).Arterialbloodgasmeasurementsdidnotdif-
fer significantly between groups, although only about
11% of patients had these done within 30 minutes of
arrivalathospital.Themeantimetobloodgasanalysis
for all samples (venous and arterial) was 1 hour
Active (titrated) (n=32) Control (high flow) (n=30)
Randomisation
Patients excluded (n=109):
  No lung function data (n=103)
  FEV1/FVC>0.7 (n=6)
Patients excluded (n=82):
  No lung function data (n=75)
  FEV1/FVC>0.7 (n=7)
Patients received non-protocol
treatment (n=25; 21%)
Patients received non-protocol
treatment (n=54; 56%)
Paramedics
Active (titrated) (n=179) Control (high flow) (n=226)
Patients included in ITT analysis (n=97) Patients included in ITT analysis (n=117)
Patients included in TPP analysis (n=43) Patients included in TPP analysis (n=92)
Patients with breathlessness
or risk or history of COPD 
Subgroup with confirmed
diagnosis of COPD
Flow of participants through study. COPD=chronic obstructive pulmonary disease; FEV1=forced
expiratory volume in one second; FVC=forced vital capacity; ITT=intention to treat;
TPP=treatment per protocol
Table 2 |Baseline characteristics for all patients and subgroup with confirmed diagnosis of
chronic obstructive pulmonary disease (COPD). Values are mean (SD) unless stated
otherwise
Characteristic Control (high flow oxygen) Active (titrated oxygen)
All patients (n= =405)
No (%) male 114/226 (50) 83/179 (46)
Age (years) 69 (10.9) (n=202) 69 (11.8) (n=152)
Prehospital treatment time (minutes) 47 (19) (n=156) 47 (18) (n=144)
Pretreatment oxygen saturation (%) 86 (13.6) (n=189) 88 (9.8) (n=160)
Confirmed diagnosis of COPD (n= =214)
No (%) male 57/117 (49) 45/97 (46)
Age (years) 68.0 (10.2) (n=117) 67.9 (10.3) (n=97)
Per cent predicted FEV1 42.1 (16.4) (n=117) 43.3 (16.5) (n=97)
Smoking history (pack years) 45.5 (26.0) (n=87) 46.3 (22.1) (n=83)
Prehospital treatment time (minutes) 47 (17) (n=87) 50 (19) (n=80)
Pretreatment oxygen saturation (%) 84 (14) (n=101) 87 (10) (n=87)
FEV1=forced expiratory volume in one second.
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oxygen group and 1 hour 46 minutes for the titrated
group. Blood samples for gas analysis were drawn
from 59/97 (61%) patients in the titrated oxygen arm
and 63/117 (54%) in the high flow arm.
In the per protocol analysis for the subgroup with
confirmed chronic obstructive pulmonary disease, we
found significant differences between treatment arms
for blood gas measurements (table 4). Patients who
received titrated oxygen were significantly less likely
to have respiratory acidosis (P=0.01) due to acute
hypercapnia(P=0.02) thanwere patientswhoreceived
high flow oxygen. We found no significant differences
between treatment arms in length of hospital stay or
requirement for ventilation for all patients or the sub-
group with confirmed chronic obstructive pulmonary
disease(table 4).Deathratesweresimilartothoseseen
in the intention to treat analysis for all patients and the
subgroupwithconfirmedchronicobstructivepulmon-
ary disease, although the differences did not reach sta-
tistical significance (table 4).
DISCUSSION
We found that oxygen treatment, titrated by para-
medics to achieve arterial oxygen saturations between
88% and 92%, for patients with breathlessness and a
history or risk of chronic obstructive pulmonary dis-
ease, reduced the risk of death from respiratory failure
by 58% for all patients and 78% for patients with con-
firmed chronic obstructive pulmonary disease, com-
pared with high flow oxygen. For high flow oxygen
treatment in patients with confirmed chronic obstruc-
tive pulmonary disease in the prehospital setting, the
number needed to harm was 14; that is, for every 14
patients who are given high flow oxygen, one will die.
Patients with chronic obstructive pulmonary disease
whoreceivedtitratedoxygenaccordingtotheprotocol
were also significantly less likely to have respiratory
acidosis or hypercapnia.
Comparison with other studies
This is the first randomised controlled trial of oxygen
treatmentforpatientswithapresumedacuteexacerba-
tion of chronic obstructive pulmonary disease in the
prehospital setting. We used mortality as the primary
outcomeforthestudybecauseitiseasilymeasuredand
islesssubjecttoconfoundingthanareotherhealthout-
comessuchaslengthofstayinhospital.Ourdeathrate
of9%inthehighflowoxygenarmissimilartothatseen
in audits of patients admitted to hospital with acute
exacerbations of chronic obstructive pulmonary
disease.
2829 Importantly, our study provides much
needed support for recent recommendations that
titrated oxygen, administered to achieve arterial oxy-
gen saturations between 88% and 92%, should be used
in emergency situations.
819
In the treatment per protocol analyses, patients with
chronic obstructive pulmonary disease who received
high flow oxygen were more likely to have respiratory
acidosis with a significantly higher arterial carbon
dioxide pressure. This is consistent with previous stu-
diesthathavefoundthatincreasedcarbondioxideand
respiratory acidosis are associated with poor out-
comes, including increased mortality.
151630 Reversal
orpreventionoftheseabnormalitiesbytitratedoxygen
has been associated with better in-hospital
survival.
193132 Although patients given high flow oxy-
gen were more acidotic, the arterial oxygen pressure
did not differ greatly between groups, which may
reflect the more rapid change that occurs in response
Table 3 |Intention to treat analysis. Values are numbers (percentages) unless stated otherwise
Control (high flow oxygen) Active (titrated oxygen) Treatment effect P value
Mortality
All patients 21/226 (9) 7/179 (4) 0.42 (0.20 to 0.89)* 0.02
Confirmed COPD 11/117 (9) 2/97 (2) 0.22 (0.05 to 0.91)* 0.04
Incidence of ventilation
All patients 19/213 (9) 13/166 (8) 0.88 (0.45 to 1.72)* 0.70
Non-invasive ventilation 7 8
Invasive ventilation 12 5
Confirmed COPD 15/105 (14) 8/84 (10) 0.67 (0.29 to 1.54)* 0.34
Non-invasive ventilation 6 5
Invasive ventilation 9 3
Length of hospital stay (mean (SD) days)
All patients 5.9 (5.6) (n=226) 5.5 (5.9) (n=179) −0.45 (0.57)† 0.19
Confirmed COPD 6.3 (5.8) (n=117) 5.4 (4.1) (n=97) −0.88 (0.70)† 0.37
Arterial blood gases (<30 min) (confirmed COPD patients)
Mean (SD) pH 7.29 (0.14) (n=19) 7.35 (0.16) (n=19) 0.06 (0.05)† 0.11
Mean (SD) carbon dioxide (mm Hg) 77.8 (49.2) (n=20) 54.7 (31.1) (n=20) −23.1 (13.0)† 0.06
Mean (SD) bicarbonate (mmol/l) 32.3 (10.1) (n=19) 26.8 (6.5) (n=19) −5.5 (2.76)† 0.07
Mean (SD) oxygen (mm Hg) (arterial only) 98.4 (46.1) (n=14) 79.3 (24.9) (n=9) −19.1 (16.8)† 0.34
COPD=chronic obstructive pulmonary disease.
*Relative risk (95% CI).
†Mean difference (SE).
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with pH and carbon dioxide.
Wefoundthatpatientswithanacuteexacerbationof
chronic obstructive pulmonary disease treated with
titratedoxygenintheprehospitalsettingforanaverage
time of 45 minutes were less likely to develop respira-
tory acidosis and die than were patients treated with
high flow oxygen. Therefore, a dispersed population
and lengthy treatment and transport times may maxi-
misethepotentialadverseeffectsofhighconcentration
oxygen treatment compared with areas and services
that may have short treatment times. The population
around Hobart is reasonably urbanised, but outlying
rural areas give a rather mixed population, ideal for a
generalisable study.
Strengths and limitations of study
Onelimitationofourtrialwasthelowerthanexpected
rate of adherence to study protocols, in both prehospi-
tal oxygen treatment and the measurement of arterial
blood gases onarrival at hospital, showing the difficul-
ties associated with modifying practice. Of the 214
patients with confirmed chronic obstructive pulmon-
ary disease, ambulance records showed that 37%
received treatment that did not comply with the study
protocol (56% in the titrated oxygen arm and 21% in
the highflow oxygen arm). In the titrated oxygenarm,
all protocol violations involved administration of high
flow oxygen at some point during prehospital treat-
ment. We expect that this would have minimised any
treatmenteffectintheintentiontotreatanalysis,butwe
still found a significant reduction in mortality for
titrated oxygen treatment. The frequent lack of com-
pliance in the titrated oxygen arm is probably a result
of the entrenched culture and training in emergency
medicine, which emphasises that high flow oxygen
will savelivesin acuterespiratoryemergenciesbypre-
venting severe hypoxaemia. From reviews of charts
andinterviewswithparamedics,wefoundnoevidence
that the breaches of protocol were a result of malfunc-
tion of monitoring of saturation (oximeter), patients
requesting more oxygen, or lack of understanding of
the protocol. However, feedback indicated that some
paramedicswereconcernedaboutinsufficientdelivery
of oxygen in distressed patients, which suggests that
they believed the entrenched cultural training that
“more is better.” This culture, combined with the
absence of high quality evidence on the potential dan-
gers of oxygen, may have been responsible for the
ongoing practice of routine delivery of high flow
oxygen.
78161719-2133-35
A second limitation of this study was the low rate of
arterial blood gas sampling for study patients.
Although we informed staff in the emergency depart-
mentstaff ofthe importance ofarterialsamples forthis
trial,compliancewaslowandonly11%ofarterialsam-
ples were drawn within 30 minutes of arrival. An audit
ofoxygentreatmentintheprehospitalsettingbyWije-
singhe et al also found a low rate of arterial blood gas
sampling for patients with acute exacerbations of
chronic obstructive pulmonary disease.
20 The authors
suggested several potential reasons for this, including
refusal by patients, reluctance of the doctor to do the
test, a perception by the doctor that the test is not indi-
cated,orlimitedtimeandstaffresources.
20Intheemer-
gency department at the time of the trial, the reasons
given mainly related to limitations in staff time and
resources but also to reluctance to do tests regarded
as not clinically indicated. This supports again the dif-
ficultyin“realworld”clinicaltrialsofgettingclinicians
Table 4 |Treatment per protocol. Values are numbers (percentages) unless stated otherwise
Control (high flow oxygen) Active (titrated oxygen) Treatment effect P value
Mortality
All patients 16/177 (9) 3/66 (5) 0.50 (0.16 to 1.54)* 0.23
Confirmed COPD 9/92 (10) 1/43 (2) 0.24 (0.04 to 1.57)* 0.14
Incidence of ventilation
All patients 19/167 (11) 5/63 (8) 0.70 (0.25 to 1.97)* 0.50
Non-invasive ventilation 7 4
Invasive ventilation 12 1
Confirmed COPD 15/83 (18) 3/40 (8) 0.42 (0.14 to 1.20)* 0.11
Non-invasive ventilation 6 2
Invasive ventilation 9 1
Length of hospital stay (mean (SD) days)
All patients 5.9 (5.5) (n=177) 6.0 (5.3) (n=66) 0.09 (0.78)† 0.87
Confirmed COPD 6.5 (6.0) (n=92) 6.2 (4.6) (n=43) −0.29 (1.04)† 0.96
Arterial blood gases (<30 min) (confirmed COPD patients)
Mean (SD) pH 7.29 (0.15) (n=18) 7.41 (0.09) (n=10) 0.12 (0.05)† 0.01
Mean (SD) carbon dioxide (mm Hg) 76.5 (50.2) (n=19) 42.9 (14.2) (n=10) −33.6 (16.3)† 0.02
Mean (SD) bicarbonate (mmol/l) 31.5 (9.9) (n=18) 26.0 (4.2) (n=10) −5.5 (3.30)† 0.15
Mean (SD) oxygen (mm Hg) (arterial only) 98.4 (46.1) (n=14) 81.5 (30.9) (n=6) −16.9 (20.7)† 0.46
COPD=chronic obstructive pulmonary disease.
*Relative risk (95% CI).
†Mean difference (SE).
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the study, as well as the difficulty in using clinical trials
to bring about change in management practices. The
British Thoracic Society’s guidelines on the manage-
ment of acute exacerbation of chronic obstructive pul-
monary disease recommend that all patients should
have arterial blood gas sampling.
8 The audit by Wije-
singheetalfoundthataboutathirdofpatientswhohad
a blood gas measurement had respiratory failure,
defined as an arterial carbon dioxide pressure of
45mmHgandapHbelow7.35,illustratingtheimpor-
tance of this recommendation.
20 Ideally, for our study,
a memberoftheresearchteamwould havebeenavail-
able to take arterial blood samples on arrival of the
studypatients,butunfortunatelythiswasnotpractical.
In this study, we could not determine any effect of
prehospital management on in-hospital management
or differentiate the effects of prehospital and in-hospi-
tal oxygen management on measured outcomes.
Review of the hospital records did not provide any
further insight into the treatment after arrival in hospi-
tal. Titratedoxygenisthe recommendedtreatmentfor
breathless patients with a history or risk of chronic
obstructive pulmonary disease at the Royal Hobart
Hospital, but in practice, especially at the time of the
trial,manyofthesepatientsreceivedhighflowoxygen
onadmissiontohospital.However,anychangeinoxy-
gen treatment that occurred after arrival in hospital
would have reduced the differences between the treat-
ment arms, thus underestimating the risk associated
with high flow oxygen. Unfortunately, collection of
data on in-hospital management was beyond the
scope of the study, so we cannot dissect the effect of
prehospital and in-hospital oxygen administration.
Conclusions and policy implications
This randomised controlled trial found that titrated
oxygen treatment in the prehospital setting resulted
ina 78%reductionin therisk ofin-hospital respiratory
failure and subsequent mortality, compared with high
flow oxygen treatment, and a decreased risk of hyper-
capnia and respiratory acidosis for patients with an
acute exacerbation of chronic obstructive pulmonary
disease. Our findingsprovide the first high quality evi-
dencefromarandomisedcontrolledtrialforthedevel-
opmentof universal guidelinesand support the British
Thoracic Society’s recent guidelines on acute oxygen
treatment, which recommend that oxygen should be
administeredonlyatconcentrationssufficienttomain-
tain adequate oxygen saturations. Although our find-
ings may need to be confirmed in larger studies across
other health systems, implementation of the new
guidelines will now be easier. However, resources for
an aggressive campaign of education will still be
needed to change the “more is better” oxygen culture
that may ignore the potential dangers of hyperoxia.
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